Latest Provectus Pharma (PVCT) Headlines Prov
Post# of 107
Posted On: 03/11/2014 3:02:55 AM
Latest Provectus Pharma (PVCT) Headlines
Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD
PR Newswire - Thu Feb 27, 8:23AM CST
Provectus Pharmaceuticals, Inc. (OTC: PVCT) The melanoma version of the drug is the closest to market release. Phase 2 data was finalized in October 2012 and the drug is being prepped for Breakthrough Therapy Designation (BTD) Drug Submission with the FDA and is in the final steps for approval. Once submitted PVCT should receive a decision within 60 days of receipt of that request.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Sanofi's CEO Admits Lackluster Drug Development Decade but Defends Its Pipeline: Sanofi (OTCQB: SNYNF), Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Feb 10, 10:12AM CST
The fierce competition coming from generic drug companies, the escalating costs of developing new drugs and the arduous process of getting them approved weighs heavily on Sanofi (OTCQB: SNYNF) and its competitors.
TrendingWallStreet.com Begins Trending PVCT, ORMP, KO, and MCIG
ACCESSWIRE - Mon Feb 03, 11:27PM CST
Whether it's a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
at The Street - Fri Jan 31, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Tranzbyte's Medical-Marijuana Dispensary Deal Falls Apart: Tranzbyte Corp. (OTCPINK: ERBB), Neutra Corp. (OTCQB: NTRR), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Thu Jan 30, 8:47AM CST
Tranzbyte Corp. (OTCPINK: ERBB) was forced to take back the good news that it had struck a deal with a medical-marijuana dispensary to use the dispensary units it sells.
CORRECTION: Provectus's PV-10 path to initial approval in US now clear per FDA meeting minutes
M2 - Tue Jan 28, 9:11AM CST
Correction to headline: Provectus Biopharmaceuticals Inc (OTC
VCT), a US-based developer of prescription drugs in oncology and dermatology, announced on Friday that it received the official minutes from a Type C meeting held with the US Food and Drug Administration (FDA) Division of Oncology Products 2, on 16 December 2013.
Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Jan 27, 2:01PM CST
Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company's share price.
Provectus announces clearance of initial approval for PV-10 in US
M2 - Mon Jan 27, 6:23AM CST
Provectus Biopharmaceuticals Inc (OTC VCT), a US-based developer of prescription drugs in oncology and dermatology, announced on Friday the receipt of the official minutes from the Type C meeting held with the US Food and Drug Administration (FDA) Division of Oncology Products 2, on 16 December 2013.
Fisking Provectus' Claims About PV-10's FDA Approval Path
at The Street - Fri Jan 24, 12:41PM CST
Another update to the Provectus PV-10 melanoma drug story.
Provectus Still Won't Answer Key Questions About Skin Cancer Drug PV-10
at The Street - Fri Jan 24, 10:49AM CST
An update to my earlier story about the obsolescence of Provectus' skin-cancer drug PV-10, including some new information about an ongoing study at the Moffitt Cancer Center.
Provectus' Wild Volume Ride Ends With 64.18% Loss for the Day: Provectus Pharmaceutical Inc. (OTCQB: PVCT), Royal Dutch Shell Plc (OTCQB: RYDAF), Fannie Mae (OTCQB: FNMA)
ACCESSWIRE - Fri Jan 24, 8:32AM CST
Despite rumors of impending good news, a favorable research report and herculean stock volume, Provectus Pharmaceutical Inc.'s (OTCQB: PVCT) stock lost 64.18% of its value when the market closed Jan. 23.
The Obsolescence of Provectus' Skin Cancer Drug Means Current Speculative Run Ends Badly
at The Street - Thu Jan 23, 10:26AM CST
Provectus' PV-10 has already been marginalized by better, more powerful skin cancer therapies.
Provectus Pharmaceuticals, Inc. Analyst Research Report
PR Newswire - Wed Jan 22, 6:00AM CST
Provectus Pharmaceuticals (OTC: PVCT), Inc., is a development-stage pharmaceutical company, that engages in developing pharmaceuticals for oncology and dermatology indications. The company's product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis; and PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis. It also develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. In addition, the company develops over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.
Provectus Type C Meeting With FDA Oncology Division Held December 16, 2013
Business Wire - Wed Dec 18, 6:10AM CST
Provectus Pharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, today announced that it held a Type C meeting with the FDA's Division of Oncology Products 2 on December 16, 2013. The purpose of the meeting was to determine which of the available paths that Provectus' novel oncology drug PV-10 will take in pursuit of FDA approval and commercialization.
Provectus changes name to Provectus Biopharmaceuticals Inc and reincorporates in Delaware
M2 - Wed Dec 18, 5:00AM CST
Provectus Pharmaceuticals Inc (OTC VCT), a development-stage oncology and dermatology biopharmaceutical company, announced on Tuesday that its shareholders in a special meeting have voted to change the company's name to Provectus Biopharmaceuticals Inc and reincorporate in Delaware, effective promptly upon regulatory filings in Delaware and Nevada.
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
Business Wire - Tue Dec 17, 5:00AM CST
Provectus Pharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that shareholders in a special meeting voted to change the Company's name to Provectus Biopharmaceuticals, Inc. and reincorporate in Delaware effective promptly upon regulatory filings in Delaware and Nevada. The company's common stock will continue to trade under the symbol "PVCT" on the Over-the-Counter exchange. The name change and reincorporation proposals both had support from over 99% of shareholders who voted.
Provectus to Hold Special Meeting of Stockholders December 16, 2013, in Knoxville, Tennessee
Business Wire - Tue Nov 05, 8:15AM CST
Provectus Pharmaceuticals, Inc. (OTCQB: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will hold a special meeting of stockholders to vote on the change of the company's name to Provectus Biopharmaceuticals, Inc. and reincorporation of the Company in the State of Delaware from the State of Nevada. The special meeting of stockholders will be held on December 16, 2013 at 4:00 pm EST at the law offices of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, which is located at 265 Brookview Centre Way, Suite 600, Knoxville, Tennessee 37819.
Small Cap Stocks In Focus - SGLB, NAMG and PVCT
ACCESSWIRE - Mon Oct 28, 12:54AM CDT
Sigma Labs, Inc. (OTC: SGLB), North American Oil and Gas Corporation (OTC: NAMG) and Provectus Pharmaceuticals (OTC: PVCT) are small cap stocks in focus.
Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD
PR Newswire - Thu Feb 27, 8:23AM CST
Provectus Pharmaceuticals, Inc. (OTC: PVCT) The melanoma version of the drug is the closest to market release. Phase 2 data was finalized in October 2012 and the drug is being prepped for Breakthrough Therapy Designation (BTD) Drug Submission with the FDA and is in the final steps for approval. Once submitted PVCT should receive a decision within 60 days of receipt of that request.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Sanofi's CEO Admits Lackluster Drug Development Decade but Defends Its Pipeline: Sanofi (OTCQB: SNYNF), Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Feb 10, 10:12AM CST
The fierce competition coming from generic drug companies, the escalating costs of developing new drugs and the arduous process of getting them approved weighs heavily on Sanofi (OTCQB: SNYNF) and its competitors.
TrendingWallStreet.com Begins Trending PVCT, ORMP, KO, and MCIG
ACCESSWIRE - Mon Feb 03, 11:27PM CST
Whether it's a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
at The Street - Fri Jan 31, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Tranzbyte's Medical-Marijuana Dispensary Deal Falls Apart: Tranzbyte Corp. (OTCPINK: ERBB), Neutra Corp. (OTCQB: NTRR), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Thu Jan 30, 8:47AM CST
Tranzbyte Corp. (OTCPINK: ERBB) was forced to take back the good news that it had struck a deal with a medical-marijuana dispensary to use the dispensary units it sells.
CORRECTION: Provectus's PV-10 path to initial approval in US now clear per FDA meeting minutes
M2 - Tue Jan 28, 9:11AM CST
Correction to headline: Provectus Biopharmaceuticals Inc (OTC
VCT), a US-based developer of prescription drugs in oncology and dermatology, announced on Friday that it received the official minutes from a Type C meeting held with the US Food and Drug Administration (FDA) Division of Oncology Products 2, on 16 December 2013. Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Jan 27, 2:01PM CST
Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company's share price.
Provectus announces clearance of initial approval for PV-10 in US
M2 - Mon Jan 27, 6:23AM CST
Provectus Biopharmaceuticals Inc (OTC
VCT), a US-based developer of prescription drugs in oncology and dermatology, announced on Friday the receipt of the official minutes from the Type C meeting held with the US Food and Drug Administration (FDA) Division of Oncology Products 2, on 16 December 2013. Fisking Provectus' Claims About PV-10's FDA Approval Path
at The Street - Fri Jan 24, 12:41PM CST
Another update to the Provectus PV-10 melanoma drug story.
Provectus Still Won't Answer Key Questions About Skin Cancer Drug PV-10
at The Street - Fri Jan 24, 10:49AM CST
An update to my earlier story about the obsolescence of Provectus' skin-cancer drug PV-10, including some new information about an ongoing study at the Moffitt Cancer Center.
Provectus' Wild Volume Ride Ends With 64.18% Loss for the Day: Provectus Pharmaceutical Inc. (OTCQB: PVCT), Royal Dutch Shell Plc (OTCQB: RYDAF), Fannie Mae (OTCQB: FNMA)
ACCESSWIRE - Fri Jan 24, 8:32AM CST
Despite rumors of impending good news, a favorable research report and herculean stock volume, Provectus Pharmaceutical Inc.'s (OTCQB: PVCT) stock lost 64.18% of its value when the market closed Jan. 23.
The Obsolescence of Provectus' Skin Cancer Drug Means Current Speculative Run Ends Badly
at The Street - Thu Jan 23, 10:26AM CST
Provectus' PV-10 has already been marginalized by better, more powerful skin cancer therapies.
Provectus Pharmaceuticals, Inc. Analyst Research Report
PR Newswire - Wed Jan 22, 6:00AM CST
Provectus Pharmaceuticals (OTC: PVCT), Inc., is a development-stage pharmaceutical company, that engages in developing pharmaceuticals for oncology and dermatology indications. The company's product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis; and PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis. It also develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. In addition, the company develops over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.
Provectus Type C Meeting With FDA Oncology Division Held December 16, 2013
Business Wire - Wed Dec 18, 6:10AM CST
Provectus Pharmaceuticals, Inc. (OTCQB
VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, today announced that it held a Type C meeting with the FDA's Division of Oncology Products 2 on December 16, 2013. The purpose of the meeting was to determine which of the available paths that Provectus' novel oncology drug PV-10 will take in pursuit of FDA approval and commercialization. Provectus changes name to Provectus Biopharmaceuticals Inc and reincorporates in Delaware
M2 - Wed Dec 18, 5:00AM CST
Provectus Pharmaceuticals Inc (OTC
VCT), a development-stage oncology and dermatology biopharmaceutical company, announced on Tuesday that its shareholders in a special meeting have voted to change the company's name to Provectus Biopharmaceuticals Inc and reincorporate in Delaware, effective promptly upon regulatory filings in Delaware and Nevada. Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
Business Wire - Tue Dec 17, 5:00AM CST
Provectus Pharmaceuticals, Inc. (OTCQB
VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that shareholders in a special meeting voted to change the Company's name to Provectus Biopharmaceuticals, Inc. and reincorporate in Delaware effective promptly upon regulatory filings in Delaware and Nevada. The company's common stock will continue to trade under the symbol "PVCT" on the Over-the-Counter exchange. The name change and reincorporation proposals both had support from over 99% of shareholders who voted. Provectus to Hold Special Meeting of Stockholders December 16, 2013, in Knoxville, Tennessee
Business Wire - Tue Nov 05, 8:15AM CST
Provectus Pharmaceuticals, Inc. (OTCQB: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will hold a special meeting of stockholders to vote on the change of the company's name to Provectus Biopharmaceuticals, Inc. and reincorporation of the Company in the State of Delaware from the State of Nevada. The special meeting of stockholders will be held on December 16, 2013 at 4:00 pm EST at the law offices of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, which is located at 265 Brookview Centre Way, Suite 600, Knoxville, Tennessee 37819.
Small Cap Stocks In Focus - SGLB, NAMG and PVCT
ACCESSWIRE - Mon Oct 28, 12:54AM CDT
Sigma Labs, Inc. (OTC: SGLB), North American Oil and Gas Corporation (OTC: NAMG) and Provectus Pharmaceuticals (OTC: PVCT) are small cap stocks in focus.
(0)
(0)Provectus Biopharmaceuticals Inc. (PVCT) Stock Research Links
Scroll down for more posts ▼